PBM reset clouds Cigna's cleanup story
- Cigna is becoming a more focused employer health and pharmacy services company after selling Medicare assets and planning to exit individual exchanges by the end of 2026.
- Evernorth still has a strong growth piece: Specialty and Care Services adjusted earnings grew 20% in Q1 2026.
- The hard part is Pharmacy Benefit Services, where pretax adjusted earnings fell 28% as pricing reset and Cigna invested in its rebate-free Signature model.
- Cigna Healthcare's Q1 2026 medical care ratio was 79.8%, but management said medical costs should stay high through the year.
- The stock is not mainly a price problem today. The bigger question is whether earnings quality can improve while the PBM model changes.
A cleanup with a margin problem
Cigna has a clear bull story. It is cutting away messier businesses, including Medicare Advantage and individual exchange plans, and leaning into employer health plans, pharmacy services, specialty drugs, and care services. That could make the company simpler and more focused.
The strongest current proof point is Specialty and Care Services inside Evernorth. In Q1 2026, that business grew pretax adjusted earnings 20%, helped by biosimilars and GLP-1 management. If that growth keeps going, it can offset some pain in the older pharmacy benefit manager business, or PBM, which manages drug benefits for health plans and employers.
The bear case is also very real. Pharmacy Benefit Services pretax adjusted earnings fell 28% in Q1 2026. The drop came from large client renewals that reset pricing lower and from investment in Signature, Cigna's rebate-free pharmacy model.
Cigna Healthcare also looked better than it may really be. Its Q1 2026 medical care ratio, the share of premiums spent on medical claims, was 79.8%. Management tied part of that strength to timing, weather, lower flu volumes, and plan mix, while still saying medical cost trends remain high.
Two engines, different pressures
Cigna makes money through two main platforms. Evernorth Health Services sells pharmacy benefit management, specialty pharmacy, drug distribution, virtual care, behavioral health, and other care services. Cigna Healthcare sells medical insurance and health plan administration to employers, individuals, and international customers.
In Pharmacy Benefit Services, Cigna earns from managing drug benefits, pharmacy networks, claims, and related services. This model is changing fast. Signature is designed to be more transparent and rebate-free, but the transition is already cutting margins.
Specialty and Care Services is the cleaner growth engine right now. Accredo specialty pharmacy, specialty drug distribution, biosimilar adoption, GLP-1 programs, and care services are helping profit grow even while the PBM piece weakens.
Cigna Healthcare earns premiums on insured plans and fees on administrative services only plans, where employers carry the claims risk. The company is focusing on employer markets, exiting individual exchanges by the end of 2026, and reviewing EviCore for a possible sale or partnership.
What Cigna sells
Pharmacy Benefit Services
This is Cigna's PBM business, which manages drug benefits, pharmacy networks, plan design, and claims. It is large, but Q1 2026 earnings fell sharply as pricing reset and Signature investment increased.
Signature rebate-free pharmacy model
Signature is Cigna's push toward a more transparent pharmacy service without traditional rebate economics. It may help Cigna keep clients as regulation changes, but it is pressuring profit during the transition.
Specialty pharmacy and drug distribution
Accredo and related specialty services handle complex, high-cost drugs. This area is benefiting from biosimilars and GLP-1 management.
Care services, behavioral health, and virtual care
These services help employers and health plans manage care, costs, and access. EviCore, a benefits management asset, is under strategic review.
U.S. employer health plans
Cigna sells insured and administrative services only health plans to employers. This is the main focus of Cigna Healthcare after the Medicare sale.
International Health
Cigna offers medical, dental, life, and related coverage outside the U.S. It is smaller than the U.S. and Evernorth businesses, but adds diversification.
Where Q1 2026 revenue sat
The mix uses Q1 2026 adjusted revenues before Corporate eliminations: Pharmacy Benefit Services $33,002 million, Specialty and Care Services $25,440 million, Cigna Healthcare $11,477 million, and Other Operations $120 million. These are segment adjusted revenues, so they can include sales between Cigna businesses.
What could break the case
PBM margin floor is lower than hoped
High impact · High oddsPharmacy Benefit Services pretax adjusted earnings fell 28% in Q1 2026. The pressure came from large client pricing resets and investment in Signature. If that margin reset lasts longer than expected, Evernorth may stop looking like Cigna's dependable growth engine.
Medical costs reappear after a strong Q1
High impact · Medium oddsCigna Healthcare reported a 79.8% medical care ratio in Q1 2026. Management said the result benefited from timing, weather, low flu volumes, and member mix, while medical cost trends remain high. If claims rise in Q2 or Q3, the insurance side may not bridge the PBM profit decline.
PBM regulation changes the profit pool
High impact · High oddsThe Consolidated Appropriations Act, 2026 requires PBMs to pass through 100% of rebates for ERISA plans starting in August 2028. That makes the old rebate model less useful. Cigna is moving first with Signature, but a required industry reset can still reduce earnings power.
Portfolio cleanup creates gaps
Medium impact · Medium oddsCigna has sold Medicare assets and plans to exit individual exchanges by the end of 2026. That can improve focus, but it can also remove revenue and change the risk mix. The EviCore review adds another moving piece.
CEO transition changes capital choices
Medium impact · Medium oddsBrian Evanko is set to take over from David Cordani. A new CEO may keep the strategy steady, or may change the pace of deals, buybacks, divestitures, and investment in Signature. The Q1 2026 filing also showed no share repurchases during the quarter, compared with 5.0 million shares repurchased in Q1 2025.
In one breath
What does Cigna actually do?
Cigna has two main businesses. Evernorth manages pharmacy benefits, specialty pharmacy, and care services, while Cigna Healthcare sells health insurance and health plan administration.
Why is Cigna's PBM business under pressure?
The PBM model is moving away from traditional rebate economics. Cigna is investing in Signature, a rebate-free pharmacy model, and large client renewals reset pricing lower in Q1 2026.
Is Cigna leaving health insurance?
No. Cigna is narrowing its insurance focus. It sold Medicare assets, plans to exit individual exchanges by the end of 2026, and is focusing more on employer and international health markets.
What is the main number to watch next?
Watch Pharmacy Benefit Services pretax adjusted income and the Cigna Healthcare medical care ratio. Together, they show whether PBM margin pressure is easing and whether medical costs are staying under control.